Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

providers and patients to better manage PKU. These programs include a state-of-the-art handheld device to measure blood Phe levels in PKU patients. Human studies are planned for 2010. Regulatory approval and commercial availability of the handheld blood Phe monitor is expected in the first half of 2011.
  • BMN-185 - IgA protease for IgA nephropathy: BioMarin is completing early preclinical work and expects to move to the next phase of research in the first half of 2010. IgA proteases have been shown to cleave IgA complexes, the deposition of which causes IgA nephropathy, an orphan kidney disorder with few treatment alternatives.
  • Additional early development candidates: BioMarin is working on multiple early development opportunities and expects to announce the next IND candidate in the first half of 2010.
  • BMN-103 - a-glucosidase (GAA) for Pompe Disease: BMN-103 is a highly phosphorylated GAA enzyme, which the company believes could result in more efficient uptake in cells and potentially lead to improved glycogen reduction in key affected muscle groups not addressed with current therapy. BioMarin continues to explore partnering options for this program.
  • 6R-BH4 Cardiovascular: BioMarin has decided to put the PAH opportunity for 6R-BH4 on hold, pending discussions with potential partners. Although the early data suggest a potential for 6R-BH4 to be a safe and efficacious therapy for PAH, BioMarin decided that the additional investment in time and resources required to demonstrate this effect is better allocated to other early pipeline candidates.
  • Non-GAAP Financial Information and Reconciliation

    The above results for the quarter and nine months ended September 30, 2009 and 2008, full year results for 2008 and financial guidance for 2009 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is cal
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. BioMarin to Present at the Oppenheimer Healthcare Conference
    2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    7. BioMarin Announces FDA Approval for Kuvan
    8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    9. Rigel Announces Presentations at Two Investor Conferences
    10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
    11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... being recalled after Health Canada tests confirmed it contains ... risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution ... the product from retail stores across Canada ... purposes, including for weight loss and increased energy. ...
    (Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
    (Date:12/24/2014)... DUBLIN , Dec. 24, 2014  Actavis ... that the Company has received a complete response ... (FDA) for its New Drug Application (NDA) for ... for the treatment of hypertension.   Photo ... we are disappointed in the receipt of a ...
    Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
    ... Fla., Oct. 9 VitalRemedyMD, a physician-established company, ... improve the quality of traditional healthcare. "We are ... of Fresenius, armamentarium in helping patients with chronic ... VitalRemedyMD. A state-of-the-art medical food, VitalProteinRx is designed ...
    ... , ... Healthcare and HHC Nutrition Services will pay the United States $1.375 ... kickbacks and assistance under the guise of a sham durable medical ... that McKesson Corp., and its affiliate MediNet Corp. provided the kickbacks ...
    Cached Medicine Technology:Fresenius Medical Care, N.A. Has Selected VitalRemedyMD's VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients 2Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services 2
    (Date:12/25/2014)... (PRWEB) December 26, 2014 This is ... of the global Sterilizers industry with a focus on ... the market status of the Sterilizers manufacturers and is ... and individuals interested in the industry. This report provides ... applications and manufacturing technology. In this part, the report ...
    (Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
    (Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
    (Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
    (Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
    Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
    ... today announced,that it has finalized an agreement with U.K.-based ... with wound dressings,manufactured by AMS., Through this collaboration, ... testing of the use of GLYC-101 with AMS, wound ... phase of testing gives rise to,favorable results, or generates ...
    ... Professor Ian Frazer has won the 2008 Prime Minister,s ... UQ,s Diamantina Institute for Cancer, Immunology and Metabolic Medicine, ... Rudd at a special ceremony in the Great Hall, ... , The Prime Minister,s Prize for Science is the ...
    ... Pa., Oct. 17 Level III Trauma,Center Accreditation ... in,Pennsylvania for the period from November 1, 2008 ... South Jackson Street, Pottsville, PA, The Pennsylvania ... by the Emergency Medical Services Act (Act 1985-45).,The ...
    ... Regional Expansion With Mobile Healthy,Living Experience in Greater ... of Grains brand announced today,their expansion into the ... a Mobile Healthy Living Experience at select Hannaford ... simple, better decisions,to improve their lifestyle and diet. ...
    ... Part of Larger Health and,Nutrition Program, HACKETTSTOWN, ... is proud to be the first confectionery company ... (GDA) nutrition labeling on,all of its chocolate, non-chocolate ... redesigned to feature new graphics on the front ...
    ... for Joint-Pain Sufferers Who are Confused and Concerned, About ... Reveals Truth About Makeup of Joint ... 17 A new Web site,dedicated to helping women fight ... to help joint-pain sufferers take control of,their lives with a ...
    Cached Medicine News:Health News:Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions 2Health News:Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions 3Health News:PM's science prize for Ian Frazer 2Health News:Level III Trauma Center Accreditation Status for Pennsylvania 2Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 2Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 3Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 2Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 3Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 4Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 5Health News:www.Joyn7030.com, A New Web Site Dedicated to Helping Women Fight Joint Pain, Launches 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: